✦ LIBER ✦

Clinical outcomes of post-remission therapy using90yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma

✍ Scribed by Eun Ji Han; Sung-Eun Lee; Sung Hoon Kim; Hyung Sun Sohn; Seung Eun Jung; Gyeongsin Park; Byung-Ock Choi; Sang-Nam Lee; Suk-Woo Yang; Kyungja Han; Seok-Goo Cho

Book ID: 105989829
Publisher: Springer
Year: 2011
Tongue: English
Weight: 313 KB
Volume: 90
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-011-1191-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

How to determine post-RCHOP therapy for

How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience

✍ Bin-Tao Huang; Qing-Chun Zeng; Jessica Yu; Zhen Xiao; Bing-Sheng Li; Chun-Lai Zh 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 443 KB

The effect of adding rituximab to CHOP-b

The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis

✍ Hisakazu Nishimori; Keitaro Matsuo; Yoshinobu Maeda; Yuichiro Nawa; Kazutaka Sun 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 201 KB